Evonik Delivers First Batch of Lipids to BioNTech for its COVID-19 Vaccine
Lipid production at Evonik’s Hanau, Germany, site was set up in eight weeks and met high-quality requirements, accelerating delivery time, which was originally set for mid-2021.
Evonik announced on April 22, 2021 that it has delivered the first batches of lipids for the Pfizer-BioNTech COVID-19 vaccine months ahead of schedule.
Under its strategic partnership with BioNTech, Evonik was tasked with producing two different lipids for the vaccine with lipid delivery scheduled for mid-2021, Evonik said in a company press release. Lipid production at Evonik’s Hanau, Germany site was set up in just eight weeks and met the high-quality requirements, allowing for the company to accelerate delivery time.
"Setting up production at this speed is a great achievement," said Christian Kullmann, chairman of Evonik's executive board, in the press release. "Increasing lipid production in Germany will also allow us to further accelerate the manufacturing of larger quantities of the vaccine. In this way, we are contributing to the fight against the pandemic."
Source: Evonik
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
